• Explore /
  • Poster
  • / Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.

Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.

Abstract Poster

Authors

null

Stefania Oliva

Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

Stefania Oliva , Davine Hofste op Bruinink , Lucie ŘÍhová , Stefano Spada , Bronno van der Holt , Rossella Troia , Manuela Gambella , Lucia Pantani , Sara Grammatico , Milena Gilestro , Massimo Offidani , Rossella Ribolla , Monica Galli , Roman Hajek , Antonio Palumbo , Michele Cavo , Paola Omedè , Vincent van der Velden , Mario Boccadoro , Pieter Sonneveld

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01208766

Citation

J Clin Oncol 35, 2017 (suppl; abstr 8011)

DOI

10.1200/JCO.2017.35.15_suppl.8011

Abstract #

8011

Poster Bd #

337

Abstract Disclosures

Similar Posters

First Author: Umberto Vitolo

Poster

2019 ASCO Annual Meeting

Minimal residual disease clinical monitoring and depth of response in multiple myeloma.

Minimal residual disease clinical monitoring and depth of response in multiple myeloma.

First Author: Joaquin Martinez-Lopez

First Author: Saad Zafar Usmani

First Author: Jeries Kort